{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:02:25Z","timestamp":1766196145078,"version":"3.48.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI134937-01A1"],"award-info":[{"award-number":["R01 AI134937-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5T32AI132165"],"award-info":[{"award-number":["5T32AI132165"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102722","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:38:57Z","timestamp":1758620337000},"page":"102722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Infection-sensing minigenome as a novel therapeutic approach against Ebola virus"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-0381","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brady N.","family":"Zell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Parrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Yamaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102722_bib1","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMoa1404505","article-title":"Emergence of Zaire Ebola virus disease in Guinea","volume":"371","author":"Baize","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102722_bib2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12879-015-1302-4","article-title":"The face of Ebola: changing frequency of haemorrhage in the West African compared with Eastern-Central African outbreaks","volume":"15","author":"Petti","year":"2015","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib3","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.3201\/eid2111.150582","article-title":"Ebola Virus Outbreak Investigation, Sierra Leone, September 28-November 11, 2014","volume":"21","author":"Lu","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2016.08.011","article-title":"Clinical profile and containment of the Ebola virus disease outbreak in two large West African cities, Nigeria, July-September 2014","volume":"53","author":"Ohuabunwo","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib5","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","article-title":"Clinical illness and outcomes in patients with Ebola in Sierra Leone","volume":"371","author":"Schieffelin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102722_bib6","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3201\/eid2209.151621","article-title":"Clinical Features of and Risk Factors for Fatal Ebola Virus Disease, Moyamba District, Sierra Leone, December 2014-February 2015","volume":"22","author":"Haaskjold","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(22)00584-9","article-title":"Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study","volume":"23","author":"Nsio","year":"2023","journal-title":"Lancet Infect. Dis."},{"year":"2008","series-title":"Filovirus Haemorrhagic Fever Guideline","author":"Sterk","key":"10.1016\/j.omtn.2025.102722_bib8"},{"key":"10.1016\/j.omtn.2025.102722_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41579-019-0233-2","article-title":"Therapeutic strategies to target the Ebola virus life cycle","volume":"17","author":"Hoenen","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.omtn.2025.102722_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","article-title":"Small molecules in the treatment of COVID-19","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2025.102722_bib12","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","article-title":"Antivirals with common targets against highly pathogenic viruses","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102722_bib13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coviro.2019.03.001","article-title":"Current status of small molecule drug development for Ebola virus and other filoviruses","volume":"35","author":"Edwards","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib14","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pharmtox-011112-140248","article-title":"Systems pharmacology to predict drug toxicity: integration across levels of biological organization","volume":"53","author":"Bai","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omtn.2025.102722_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.omtn.2025.102722_bib16","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1038\/s41467-020-17446-4","article-title":"Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment","volume":"11","author":"Cross","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102722_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102722_bib18","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102722_bib19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin. Med."},{"key":"10.1016\/j.omtn.2025.102722_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s43556-024-00210-1","article-title":"Monoclonal antibodies: From magic bullet to precision weapon","volume":"5","author":"Aboul-Ella","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.omtn.2025.102722_bib21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1473-3099(23)00552-2","article-title":"Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study","volume":"24","author":"Nkuba-Ndaye","year":"2024","journal-title":"Lancet Infect. Dis."},{"author":"Eisele","key":"10.1016\/j.omtn.2025.102722_bib22"},{"key":"10.1016\/j.omtn.2025.102722_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01627-23","article-title":"Translational success of fundamental virology: a VSV-vectored Ebola vaccine","volume":"98","author":"Anderson","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib24","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib25","first-page":"776","article-title":"Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report","volume":"373","author":"Ledgerwood","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102722_bib26","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102722_bib27","doi-asserted-by":"crossref","first-page":"8756","DOI":"10.1128\/JVI.72.11.8756-8764.1998","article-title":"Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes","volume":"72","author":"Muhlberger","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib28","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1128\/JVI.79.7.4425-4433.2005","article-title":"RNA polymerase I-driven minigenome system for Ebola viruses","volume":"79","author":"Groseth","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib29","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1128\/JVI.73.3.2333-2342.1999","article-title":"Comparison of the Transcription and Replication Strategies of Marburg Virus and Ebola Virus by Using Artificial Replication Systems","volume":"73","author":"Muhlberger","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.antiviral.2011.06.003","article-title":"Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses","volume":"91","author":"Hoenen","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.omtn.2025.102722_bib31","series-title":"Fields Virology","article-title":"Filoviridae: Marburg and ebola viruses","author":"Feldmann","year":"2013"},{"key":"10.1016\/j.omtn.2025.102722_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.virol.2010.04.002","article-title":"Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription","volume":"403","author":"Hoenen","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.omtn.2025.102722_bib33","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.1128\/JVI.00051-06","article-title":"Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24","volume":"80","author":"Hoenen","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib34","doi-asserted-by":"crossref","first-page":"13421","DOI":"10.1128\/JVI.79.21.13421-13433.2005","article-title":"VP24 of Marburg virus influences formation of infectious particles","volume":"79","author":"Bamberg","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib35","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102722_bib36","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1086\/504267","article-title":"Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference","volume":"193","author":"Geisbert","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib37","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1093\/nar\/gkh813","article-title":"Synthetic tRNALys,3 as the replication primer for the HIV-1HXB2 and HIV-1Mal genomes","volume":"32","author":"Miller","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102722_bib38","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1093\/nar\/gkm103","article-title":"Optimization and characterization of tRNA-shRNA expression constructs","volume":"35","author":"Scherer","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102722_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.610617","article-title":"Hijacking tRNAs From Translation: Regulatory Functions of tRNAs in Mammalian Cell Physiology","volume":"7","author":"Avcilar-Kucukgoze","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omtn.2025.102722_bib40","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1073\/pnas.89.17.8006","article-title":"Targeted cleavage of mRNA by human RNase P","volume":"89","author":"Yuan","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102722_bib41","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.bbagrm.2011.11.003","article-title":"Of P and Z: mitochondrial tRNA processing enzymes","volume":"1819","author":"Rossmanith","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2025.102722_bib42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and Mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102722_bib43","doi-asserted-by":"crossref","first-page":"10511","DOI":"10.1128\/JVI.01272-14","article-title":"A Novel Life Cycle Modeling System for Ebola Virus Shows a Genome Length-Dependent Role of VP24 in Virus Infectivity","volume":"88","author":"Watt","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib44","article-title":"Development of a Pentacistronic Ebola Virus Minigenome and Its Application to Model Mouse-Adapted Ebola Virus","volume":"2024","author":"Zell","year":"2024","journal-title":"Preprints"},{"key":"10.1016\/j.omtn.2025.102722_bib45","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.cell.2018.08.044","article-title":"Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication","volume":"175","author":"Batra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102722_bib46","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020105658","article-title":"Non-canonical proline-tyrosine interactions with multiple host proteins regulate Ebola virus infection","volume":"40","author":"Batra","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.omtn.2025.102722_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03294-21","article-title":"Defective Interfering Viral Particle Treatment Reduces Clinical Signs and Protects Hamsters from Lethal Nipah Virus Disease","volume":"13","author":"Welch","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.omtn.2025.102722_bib48","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1093\/infdis\/jiz564","article-title":"Inhibition of Nipah Virus by Defective Interfering Particles","volume":"221","author":"Welch","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/v14020383","article-title":"Virus-like Particles: Measures and Biological Functions","volume":"14","author":"Bhat","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.omtn.2025.102722_bib50","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.cell.2021.11.004","article-title":"Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance","volume":"184","author":"Chaturvedi","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2025.102722_bib51","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1038\/s41467-021-22341-7","article-title":"Defective viral genomes as therapeutic interfering particles against flavivirus infection in mammalian and mosquito hosts","volume":"12","author":"Rezelj","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102722_bib52","article-title":"Discovery and Engineering of a Therapeutic Interfering Particle (TIP): a combination self-renewing antiviral","author":"Tanner","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtn.2025.102722_bib53","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-02847-1","article-title":"Sudan Ebola virus (SUDV) outbreak in Uganda, 2022: lessons learnt and future priorities for sub-Saharan Africa","volume":"21","author":"Bwire","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.omtn.2025.102722_bib54","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1046\/j.1365-3156.2002.00944.x","article-title":"An outbreak of Ebola in Uganda","volume":"7","author":"Okware","year":"2002","journal-title":"Trop. Med. Int. Health"},{"year":"2023","series-title":"Disease Outbreak News; Marburg virus disease - the United Republic of Tanzania","key":"10.1016\/j.omtn.2025.102722_bib55"},{"year":"2021","series-title":"Disease Outbreak News; Marburg virus disease-Guinea","key":"10.1016\/j.omtn.2025.102722_bib56"},{"key":"10.1016\/j.omtn.2025.102722_bib57","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.virol.2004.11.018","article-title":"A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire","volume":"332","author":"Boehmann","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.omtn.2025.102722_bib58","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1099\/jgv.0.001261","article-title":"Assessment of the function and intergenus-compatibility of Ebola and Lloviu virus proteins","volume":"100","author":"Kamper","year":"2019","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib59","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.celrep.2018.08.008","article-title":"A Chimeric Lloviu Virus Minigenome System Reveals that the Bat-Derived Filovirus Replicates More Similarly to Ebolaviruses than Marburgviruses","volume":"24","author":"Manhart","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2025.102722_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virol.2017.06.002","article-title":"Ebolavirus protein VP24 interferes with innate immune responses by inhibiting interferon-lambda1 gene expression","volume":"509","author":"He","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.omtn.2025.102722_bib61","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1128\/JVI.01372-09","article-title":"Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling","volume":"84","author":"Mateo","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib62","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1128\/JVI.02349-05","article-title":"Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation","volume":"80","author":"Reid","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib63","doi-asserted-by":"crossref","first-page":"e01715-16","DOI":"10.1128\/JVI.01715-16","article-title":"VP24-Karyopherin Alpha Binding Affinities Differ between Ebolavirus Species, Influencing Interferon Inhibition and VP24 Stability","volume":"91","author":"Schwarz","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrd.2017.251","article-title":"Post-exposure treatments for Ebola and Marburg virus infections","volume":"17","author":"Cross","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2025.102722_bib65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.antiviral.2018.12.006","article-title":"Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets","volume":"162","author":"Basler","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.omtn.2025.102722_bib66","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102722_bib67","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102722_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001997","article-title":"Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial","volume":"13","author":"Dunning","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.omtn.2025.102722_bib69","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4184","article-title":"Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA","volume":"11","author":"Everton","year":"2021","journal-title":"Bio. Protoc."},{"key":"10.1016\/j.omtn.2025.102722_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009706","article-title":"Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA","volume":"6","author":"Thi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102722_bib71","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nature14442","article-title":"Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates","volume":"521","author":"Thi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2025.102722_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102601","article-title":"Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients","volume":"52","author":"Scott","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtn.2025.102722_bib73","article-title":"Reducing Off-target Expression of mRNA Therapeutics and Vaccines in the Liver with MicroRNA Binding Sites","volume":"33","author":"Brian","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102722_bib74","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.omtm.2023.06.005","article-title":"Lipid nanoparticle mRNA systems containing high levels of sphingomyelin engender higher protein expression in hepatic and extra-hepatic tissues","volume":"30","author":"Chander","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2025.102722_bib75","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102722_bib76","first-page":"227","article-title":"Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus","volume":"76","author":"Johnson","year":"1995","journal-title":"Int. J. Exp. Pathol."},{"key":"10.1016\/j.omtn.2025.102722_bib77","first-page":"279","article-title":"Marburg virus infection in monkeys. Ultrastructural studies","volume":"24","author":"Murphy","year":"1971","journal-title":"Lab. Invest."},{"key":"10.1016\/j.omtn.2025.102722_bib78","first-page":"805","article-title":"Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells","volume":"121","author":"Davis","year":"1997","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.omtn.2025.102722_bib79","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/BF01718224","article-title":"Respiratory Marburg virus infection in guinea pigs","volume":"141","author":"Ryabchikova","year":"1996","journal-title":"Arch. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib80","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/BF01718165","article-title":"Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis","volume":"141","author":"Ryabchikova","year":"1996","journal-title":"Arch. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib81","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/514293","article-title":"An analysis of features of pathogenesis in two animal models of Ebola virus infection","volume":"179","author":"Ryabchikova","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib82","first-page":"140","article-title":"Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure","volume":"120","author":"Jaax","year":"1996","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.omtn.2025.102722_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh4057","article-title":"Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination","volume":"9","author":"Welch","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102722_bib84","doi-asserted-by":"crossref","first-page":"e01884-19","DOI":"10.1128\/JVI.01884-19","article-title":"A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques","volume":"94","author":"Singh","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2025.102722_bib85","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102722_bib86","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41541-022-00512-x","article-title":"A single immunization with a modified vaccinia Ankara vectored vaccine producing Sudan virus-like particles protects from lethal infection","volume":"7","author":"Malherbe","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.omtn.2025.102722_bib87","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola Virus-Like Particle-Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.omtn.2025.102722_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125002768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T01:59:16Z","timestamp":1766195956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125002768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125002768"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102722","relation":{},"ISSN":["2162-2531"],"issn-type":[{"type":"print","value":"2162-2531"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infection-sensing minigenome as a novel therapeutic approach against Ebola virus","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102722"}}